Avalyn Pharma Inc. (AVLN)Healthcare | Biotechnology | Boston, United States | NasdaqGS
24.64 USD
+0.95
(4.010%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:51 a.m. EDT
Despite a 'strong buy' analyst consensus and a lofty $62 price target, Avalyn Pharma is a dangerous speculative vehicle for investors seeking capital preservation. The company is burning cash aggressively with negative operating cash flow and no path to profitability visible in the near term, while trading at a premium to its book value. The recent price action confirms a brutal rejection of higher levels; the stock has fallen nearly 20% from its 52-week high and is currently trading significantly below its 50-day moving average, indicating persistent selling pressure. The options market agrees with the bears, with massive open interest clusters at $30 and $35 acting as formidable ceilings that have repeatedly capped rallies. With no dividend to cushion the blow and a balance sheet that is merely solvent rather than robust, the risk/reward profile is skewed heavily against the buyer. This is a high-risk venture play suitable only for those willing to accept total loss potential in exchange for a lottery-ticket chance at a clinical success, not a standard investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.158787 |
| AutoETS | 0.165596 |
| AutoARIMA | 0.165599 |
| AutoTheta | 0.179204 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 70.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.113 |
| Excess Kurtosis | -1.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.295 |
| Market Cap | 1,092,367,488 |
| Forward P/E | -12.97 |
| Website | https://www.avalynpharma.com |
As of Oct. 10, 2026, 5:51 a.m. EDT: Speculators are positioning for a downside gap fill rather than a breakout. Heavy open interest sits at the $30 and $35 strikes for both calls and puts, creating a dense wall of resistance and profit-taking targets. While there is some volume in the $20-$25 put zone, the overwhelming majority of positioning is OTM, suggesting traders expect the stock to drift lower toward these established levels before any recovery attempt. Implied volatility is elevated, reflecting uncertainty around the recent post-IPO performance.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.1644625 |
| Address1 | 105 W First Street |
| All Time High | 40.17 |
| All Time Low | 22.68 |
| Ask | 24.25 |
| Ask Size | 1 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 354,700 |
| Average Daily Volume3 Month | 244,278 |
| Average Volume | 244,278 |
| Average Volume10Days | 354,700 |
| Bid | 23.92 |
| Bid Size | 1 |
| Book Value | 8.985 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 24.64 |
| Current Ratio | 33.119 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 24.91 |
| Day Low | 23.585 |
| Debt To Equity | 4.295 |
| Display Name | Avalyn Pharma |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -109,802,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.895 |
| Enterprise Value | 757,051,456 |
| Eps Current Year | -1.94 |
| Eps Forward | -1.9 |
| Eps Trailing Twelve Months | -2.47 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 32.6162 |
| Fifty Day Average Change | -7.9762 |
| Fifty Day Average Change Percent | -0.24454719 |
| Fifty Two Week Change Percent | -16.44625 |
| Fifty Two Week High | 40.17 |
| Fifty Two Week High Change | -15.529999 |
| Fifty Two Week High Change Percent | -0.3866069 |
| Fifty Two Week Low | 22.68 |
| Fifty Two Week Low Change | 1.9599991 |
| Fifty Two Week Low Change Percent | 0.08641971 |
| Fifty Two Week Range | 22.68 - 40.17 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,777,555,800,000 |
| Float Shares | 27,409,823 |
| Forward Eps | -1.9 |
| Forward P E | -12.968421 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 55 |
| Fullday Change | 0.94999886 |
| Fullday Change Percent | 4.010126 |
| Fullday Price | 24.64 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 1.0401 |
| Implied Shares Outstanding | 44,333,095 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-04-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts. |
| Long Name | Avalyn Pharma Inc. |
| Market | us_market |
| Market Cap | 1,092,367,488 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_224094665 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -103,314,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,317,579,583 |
| Number Of Analyst Opinions | 5 |
| Open | 23.88 |
| Operating Cashflow | -97,479,000 |
| Operating Margins | 0.0 |
| Phone | (206) 707-0340 |
| Previous Close | 23.69 |
| Price Eps Current Year | -12.70103 |
| Price Hint | 2 |
| Price To Book | 2.7423484 |
| Profit Margins | 0.0 |
| Quick Ratio | 32.76 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.949999 |
| Regular Market Change Percent | 4.01013 |
| Regular Market Day High | 24.91 |
| Regular Market Day Low | 23.585 |
| Regular Market Day Range | 23.585 - 24.91 |
| Regular Market Open | 23.88 |
| Regular Market Previous Close | 23.69 |
| Regular Market Price | 24.64 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 199,362 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 44,333,095 |
| Shares Percent Shares Out | 0.056799997 |
| Shares Short | 2,516,254 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,930,246 |
| Short Name | Avalyn Pharma Inc. |
| Short Percent Of Float | 0.056799997 |
| Short Ratio | 9.45 |
| Source Interval | 15 |
| State | MA |
| Symbol | AVLN |
| Target High Price | 80.0 |
| Target Low Price | 52.0 |
| Target Mean Price | 61.8 |
| Target Median Price | 60.0 |
| Total Cash | 352,424,992 |
| Total Cash Per Share | 7.949 |
| Total Debt | 17,109,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 30.420086 |
| Two Hundred Day Average Change | -5.7800865 |
| Two Hundred Day Average Change Percent | -0.19000888 |
| Type Disp | Equity |
| Volume | 199,362 |
| Website | https://www.avalynpharma.com |
| Zip | 2,127 |